Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 3

Multiple sclerosis presented as clinically isolated syndrome: the need for early diagnosis and treatment

Authors Sigliti-Henrietta Pelidou, Sotirios Giannopoulos, Sotiria Tzavidi, Georgios Lagos, Athanassios P Kyritsis

Published 6 June 2008 Volume 2008:4(3) Pages 627—630

DOI https://doi.org/10.2147/TCRM.S2515

Sigliti-Henrietta Pelidou, Sotirios Giannopoulos, Sotiria Tzavidi, Georgios Lagos, Athanassios P Kyritsis

Department of Neurology, University of Ioannina School of Medicine, Greece

Objective: To aid in the timely diagnosis of patients who present with clinically isolated syndrome (CIS).

Patients and methods: We studied 25 patients (18 women, 7 men), originally presented in our clinic with a CIS suggestive of multiple sclerosis (MS). All patients underwent the full investigation procedure including routine tests, serology, cerebrospinal fluid (CSF) examinations, evoked potentials (EPs), and magnetic resonance imaging (MRI) of brain and cervical spinal cord. Patients were imaged at baseline, and every three months thereafter up to a year.

Results: The CIS was consisted of optic neuritis in 12 cases, incomplete transverse myelitis (ITM) in 7 cases, Lhermitte sign in 2 cases, internuclear ophthalmoplegia (INO) in 2 cases, mild brainstem syndrome in 1 case, and tonic-clonic seizures in 1 case. Using the baseline and three-month scans 18/25 (72%) patients developed definite MS in one year of follow up while 7 (28%) had no further findings during this observation period. Immunomodulatory treatments were applied to all definite MS patients.

Conclusion: In light of new treatments available, MRIs at 3 month intervals are helpful to obtain the definite diagnosis of MS as early as possible.

Keywords: multiple sclerosis, clinically isolated syndrome, optic neuritis, transverse myelitis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Passing through the renal clearance barrier: toward ultrasmall sizes with stable ligands for potential clinical applications

Zhang XD, Yang J, Song SS, Long W, Chen J, Shen X, Wang H, Sun YM, Liu PX, Fan S

International Journal of Nanomedicine 2014, 9:2069-2072

Published Date: 25 April 2014

Use of immunomagnetic reduction for C-reactive protein assay in clinical samples

Chang CH, Lai ZX, Lin HL, Yang CC, Chen HH, Yang SY, Horng HE, Hong CY, Yang HC, Lin HC

International Journal of Nanomedicine 2012, 7:4335-4340

Published Date: 6 August 2012

Posaconazole in the management of refractory invasive fungal infections

Stefan Langner, Philipp B Staber, Peter Neumeister

Therapeutics and Clinical Risk Management 2008, 4:747-757

Published Date: 8 August 2008

An “acquired” hemoglobin J variant in a sickle cell disease patient

Nawwar Swedan, Kathleen Nicol, Phylis Moder, Samir Kahwash

Therapeutics and Clinical Risk Management 2008, 4:649-652

Published Date: 6 June 2008

A review of nasal polyposis

Jonathan Ray Newton, Kim Wong Ah-See

Therapeutics and Clinical Risk Management 2008, 4:507-512

Published Date: 11 April 2008

A review of the use of adapalene for the treatment of acne vulgaris

Suleyman Piskin, Erol Uzunali

Therapeutics and Clinical Risk Management 2007, 3:621-624

Published Date: 15 September 2007